Clinical Trial Update: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hepatic arterial infusion chemotherapy combined with Camrelizumab and Rivoceranib for advanced mixed hepatocellular-cholangi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Hepatocellular-cholangiocarcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Rivoceranib (rivoceranib)

Snippet

Sponsor: Fudan University | Conditions: Mixed Hepatocellular-cholangiocarcinoma | Phase 2 | Status: RECRUITING